Safety Profile Overview
SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease across multiple pivotal trials.
Generic Name
dapagliflozin
Brand Names
Farxiga
Therapeutic Class
SGLT2 Inhibitor
Manufacturer
AstraZeneca
What Pharma Signal Tracks for Farxiga
- Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Farxiga, including serious outcomes, hospitalizations, and deaths.
- FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Farxiga products.
- Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
- Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
- Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
- Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.
Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.
Get Farxiga Safety Data via API
One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Farxiga.
curl "https://api.pharma-signal.com/drug/safety/farxiga" \ -H "X-API-Key: your_key" # Returns risk score, adverse event counts, # serious/death rates, recalls, and signals
Related Safety Intelligence
Pharma Signal provides comparative analysis across therapeutic classes. Compare Farxiga against other SGLT2 Inhibitor drugs, or explore the full manufacturer portfolio for AstraZeneca.
- Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
- Therapeutic class benchmarking — See how Farxiga ranks within SGLT2 Inhibitor on serious event rates.
- Company portfolio risk — View all drugs from AstraZeneca with aggregate risk exposure.
- AI analyst briefs — Get a natural-language safety assessment combining all data sources.